The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?

Breath analysis is a promising non-invasive method for the detection and management of lung cancer. Exhaled breath contains a complex mixture of volatile and non-volatile organic compounds that are produced as end-products of metabolism. Several studies have explored the patterns of these compounds and have postulated that a unique breath signature is emitted in the setting of lung cancer.

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials.

The coronavirus disease 2019 (COVID-19) pandemic has caused considerable global disruption to clinical practice. This article will review the impact that the pandemic has had on oncology clinical trials. It will assess the effect of the COVID-19 situation on the initial presentation and investigation of patients with suspected cancer.

Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.

Aberrant immune synapse formation between antigen-presenting and immune effector cells is a central mediator of immune dysfunction and can be observed across several haematologic malignancies. Here, we describe the cell preparation, conjugation and immune synapse quantification of B and T cells obtained from patients with leukaemia and the adaptions required when using cells from murine models of disease.

Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.

There have been significant advances in our understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) over the last decade, which has been accompanied by a rapid increase in treatment options. Inhibitors of BCRsignaling such as ibrutinib and idelalisib, and pro-apoptotic agents such as ABT- 199 have shown great promise in initial clinical trials and have been at the forefront of recent developments. However, despite the encouraging early data, these agents do not appear to represent a "cure" for CLL and mechanisms of resistance to these agents have already been identified.

Chronic lymphocytic leukemia: an update on biology and treatment.

Combination chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) has emerged as the current standard of care in the treatment of chronic lymphocytic leukemia (CLL). Despite very high response rates, this treatment is too toxic for many patients, and it remains unclear as how to manage patients who do not respond to these agents or who relapse early after treatment. An increase in our understanding of the biology of CLL has led to the development of a wide range of therapies aimed at specific defects in this disease.